$1.09 Billion is the total value of Casdin Capital, LLC's 32 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 27.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SRPT | Sell | SAREPTA THERAPEUTICS INC | $86,457,000 | -99.9% | 670,000 | -23.9% | 7.95% | +15.9% |
MYOK | Sell | MYOKARDIA INC | $73,249,000 | -99.9% | 1,005,000 | -9.9% | 6.74% | +11.9% |
ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $59,313,000 | -99.9% | 515,000 | -14.2% | 5.45% | +9.2% |
NVTA | Sell | INVITAE CORP | $58,687,000 | -99.9% | 3,638,388 | -5.2% | 5.40% | -29.5% |
CNST | Sell | CONSTELLATION PHARMCETICLS I | $57,132,000 | -99.4% | 1,212,734 | -20.4% | 5.25% | +415.6% |
AGIO | Sell | AGIOS PHARMACEUTICALS INC | $39,394,000 | -99.9% | 825,000 | -11.8% | 3.62% | +15.6% |
SAGE | Sell | SAGE THERAPEUTICS INC | $16,604,000 | -100.0% | 230,000 | -42.5% | 1.53% | -73.7% |
VYGR | Sell | VOYAGER THERAPEUTICS INC | $15,276,000 | -99.9% | 1,095,075 | -2.9% | 1.40% | -30.1% |
EDIT | Exit | EDITAS MEDICINE INC | $0 | – | -415,000 | -100.0% | -0.98% | – |
FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -820,000 | -100.0% | -1.54% | – |
ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -863,300 | -100.0% | -8.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
CODEXIS INC | 22 | Q3 2023 | 8.1% |
SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-02 |
SC 13G | 2024-04-18 |
SC 13D/A | 2024-04-08 |
4 | 2024-03-28 |
3 | 2024-03-25 |
4 | 2024-03-25 |
4 | 2024-03-20 |
SC 13D/A | 2024-03-20 |
4 | 2024-03-06 |
4 | 2024-03-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.